Transient Abnormal Myelopoiesis: A Varied Spectrum of Clinical Presentation

Transient myeloproliferative disorder (TMD) is a condition seen almost exclusively in newborns with Down syndrome (DS). It can have a spectrum of clinical presentation ranging from being asymptomatic with incidental detection to a stormy course and fatal outcome. We describe three cases of TMD having different clinical presentation, course, complications and outcome. All but one had Down’s phenotype; one of them had a severe disease with tumor lysis syndrome and died of liver failure, while the other one had pericardial effusion and cardiac failure but survived. The third patient had a very benign course of illness requiring only supportive care. Newborns with DS should be screened for TMD by a complete blood count during their first month of life, irrespective of symptoms. With increasing knowledge about the natural history and management guidelines, the prognosis of this rare and unique entity has improved in recent years.

[1]  J. Vergilio,et al.  Transient abnormal myelopoiesis in neonates: GATA get the diagnosis. , 2014, Archives of pathology & laboratory medicine.

[2]  P. Heimann,et al.  Transient leukemia in a newborn without Down syndrome: case report and review of the literature , 2014, European Journal of Pediatrics.

[3]  Y. Hayashi,et al.  Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis , 2014, International Journal of Hematology.

[4]  F. Smith,et al.  Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder , 2012, British journal of haematology.

[5]  R. Arceci,et al.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. , 2011, Blood.

[6]  A. Tragiannidis,et al.  Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report , 2011, Journal of medical case reports.

[7]  S. Mahmood,et al.  Clinicopathological features of transient myeloproliferative syndrome and congenital leukaemia. , 2010, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[8]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[9]  D. Reinhardt,et al.  Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar Blasts , 2005, Klinische Padiatrie.

[10]  A. Zipursky,et al.  Telomerase and the Benign and Malignant Megakaryoblastic Leukemias of Down Syndrome , 2002, Journal of pediatric hematology/oncology.

[11]  M. Digilio,et al.  Health Supervision for Children With Down Syndrome , 1994, Pediatric Clinical Practice Guidelines & Policies.